Ignite Creation Date:
2025-12-25 @ 2:31 AM
Ignite Modification Date:
2025-12-26 @ 1:07 AM
Study NCT ID:
NCT04265534
Status:
TERMINATED
Last Update Posted:
2022-09-21
First Post:
2020-02-07
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
Sponsor:
Calithera Biosciences, Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-07-24
Start Date Type:
ACTUAL
Primary Completion Date:
2021-11-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-02-09
Completion Date Type:
ACTUAL
First Submit Date:
2020-02-07
First Submit QC Date:
None
Study First Post Date:
2020-02-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2022-09-15
Disp First Post Date Type:
None
Last Update Submit Date:
2022-09-15
Last Update Post Date:
2022-09-21
Last Update Post Date Type:
ACTUAL